A follow-up study of ENBREL (etanercept) treatment for chronic heart failure found sustained improvement in New York Heart Association (NYHA) class and no increase in adverse events. The study involved 12 patients treated with ENBREL for nine months, showing continued tolerability of the drug.
A phase II clinical trial of ENBREL (etanercept) in patients with psoriasis and psoriatic arthritis has shown promising results. The U.S. Food and Drug Administration has approved ENBREL to treat moderately to severely active rheumatoid arthritis, as well as a new indication for juvenile rheumatoid arthritis.
The Phase I/II study of NUVANCE in adult patients with moderate asthma demonstrated the potential of IL-4 inhibition to improve lung function and control asthma symptoms. Dr. Jonathan Corren and Dr. Jan Agosti presented results at the AAAAI Annual Meeting.
New research suggests that inhibiting tumor necrosis factor (TNF) may improve signs and symptoms of chronic heart failure. Studies using ENBREL, a TNF receptor inhibitor, have shown promising results in patients with moderate heart failure.
A Phase I/II trial of NUVANCE, an investigational once-a-week inhaled asthma treatment, suggests the drug helped stabilize lung function for up to 12 weeks following discontinuation of inhaled corticosteroids. The treatment was generally well tolerated, with minimal decline in forced expiratory volume.
A Phase I study published in Circulation demonstrates that ENBREL improves quality of life scores and increases functional status in patients with advanced heart failure. The study found no significant adverse effects from ENBREL treatment, suggesting a potential therapeutic benefit for chronic heart failure patients.
The US FDA approves ENBREL, a biologic response modifier, for moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients with an inadequate response to other treatments. The treatment has shown a clinical response in 74% of study participants.
Patients with secondary progressive multiple sclerosis treated with Novantrone experienced a sustained reduction in their number of attacks and delay in disability progression compared to those treated with placebo. The treatment resulted in generally manageable side effects and a smaller number of relapses in the third year.
The six-month study demonstrated significant improvement in symptoms and disease activity in patients with rheumatoid arthritis, establishing a foundation for FDA approval of ENBREL. The results support the use of etanercept as an additional treatment option for these patients.
A Phase II/III clinical trial with ENBREL (etanercept) in chronic heart failure patients is underway, based on positive results from a Phase I study. The trial aims to evaluate cytokine inhibition as a new approach to studying chronic heart failure.
A preclinical study published in Nature Medicine demonstrated that Immunex's TRAIL molecule suppresses tumor growth and induces complete remission in a high proportion of treated mice. The study shows promise for the treatment of various cancers, with the potential for minimal toxicity.